BioSpace News Archive

Theseus Pharmaceuticals, Inc. today announced that Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus, will participate in a virtual fireside chat for the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14-18, 2022.

Cybin Inc. today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to the Company’s investigational deuterated forms of DMT and 5-MeO-DMT.

Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, today launches Perturba Therapeutics Inc. (“Perturba”), a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research.

89bio, Inc. announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00 PM ET.

Selecta Biosciences, Inc. announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

CytoImmune Therapeutics announced that the executive management team will participate in the BIO CEO & Investor Conference and the 11th Annual SVB Leerink Global Healthcare Conference.

Vincerx Pharma, Inc. announced that Vincerx’s management team will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-tumor activity of the Company’s siRNA drug candidate, STP707 with intravenous administration in the United States.

Phoenix Molecular Designs, a clinical stage biopharmaceutical company dedicated to developing precise cancer therapeutics, announced the completion of patient enrollment and dosing of PMD-026 in their Phase 1b monotherapy clinical trial.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that company management is scheduled to webcast a presentation from the 11th Annual SVB Leerink Global Healthcare Conference.